

PRESS RELEASE

Cebiotex kicks off a €4 million Series A round to speed up clinical trials for its first oncology treatment

- The funds raised in this latest round, the first in which Cebiotex is seeking investment from abroad, will enable the company to speed up CEB-01 patient trials for treating soft-tissue sarcomas (STS) and develop new applications for pancreatic cancer and glioblastoma.
- This is the first therapeutic application of CEB-01, a smart, biocompatible and biodegradable nanofiber fabric for local delivery of chemotherapy after tumor removal, and developed entirely by the company using its innovative Cebiotex® technology, which has been patented in the United States, the European Union and China.
- Since it began operating in 2015, Cebiotex has completed three funding rounds coming to €4.3 million, which has enabled it to develop a GMP-certified pre-industrial pilot plant for the production of CEB-01; achieve orphan drug designation from the EMA for the indication of soft-tissue sarcomas, and begin Phase I/IIa clinical trials at Hospital de la Santa Creu i Sant Pau in Barcelona.

Barcelona, 29th January 2020. [Cebiotex](#), which is headquartered in the [Barcelona Science Park \(PCB\)](#), has kicked off a Series A funding round in which it hopes to raise €4 million. Its intention is to speed up clinical development of CEB-01 for treating soft-tissue sarcomas (STS) and bring new pancreatic cancer and glioblastoma applications to preclinical phases.

CEB-01 is a smart, biocompatible and biodegradable nanofiber fabric for local delivery of chemotherapy immediately after tumor removal, and developed entirely by the company using its innovative [Cebiotex® technology](#). CEB-01 delivers a local concentration 1,000 times higher than chemotherapy, with no side effects and without altering the standard treatment. It acts in the first weeks after surgery, when there is no set treatment, and has achieved highly promising levels of efficacy in preclinical models.

Alongside conducting clinical trials of CEB-01 for soft-tissue sarcomas, a rare type of cancer that starts in adipose, muscular, fibrous, nervous, connective and other types of tissue, Cebiotex is also working on its application for pancreatic cancer and glioblastoma, a very aggressive malignant brain tumor.

Since it began operating in 2015, Cebiotex has completed three funding rounds, raising around €4.3 million from public and private sources.

This funding has enabled it to secure [GMP \(Good Manufacturing Practice\)](#) certification from the Spanish Agency for Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) for the production of its Cebiotex® technology; [orphan drug designation](#) by the European Medicines Agency (EMA) for CEB-01 in soft-tissue sarcoma; and approval from the AEMPS to begin Phase I/IIa clinical trials in this indication at [Hospital de la Santa Creu i Sant Pau](#) in Barcelona, as a referral hospital.

“Cebiotex has completed a highly successful first stage in which we have achieved all our targets,” says Joan Bertran, CEO and co-founder of Cebiotex. “We have brought our first drug candidate, CEB-01, to clinical phases and reduced the project’s technological risk. Now we need to build up ‘financial muscle’ and grow. In this new round, international funds that we have been liaising with will take an equity stake for the first time at Cebiotex. The challenge in the immediate future is to sign pre-market licensing agreements with pharmaceutical firms to deliver sustained value to our partners and investors and ensure the project’s financial feasibility.”

Cebiotex has patented its technological drug delivery platform in the United States, the European Union and China and has a pre-industrial pilot plant. The company develops, produces and tests CEB-01 in its entirety: it designs the nanofiber production units, the development process for its therapeutic applications and characterization at the preclinical and clinical level. All its products are protected by patents and new patent applications. All its products are protected by patents and new patent applications.

“Cebiotex now has the potential and know-how to design and build specific production teams for each of CEB-01’s therapeutic applications,” notes Bertran. “This is one of our characteristic features, setting us apart from scientific teams who do not have ‘technological muscle’ in the application of nanofibers in the health sector.”

■ About Cebiotex

Cebiotex (<http://www.cebiotex.com>) was founded in 2012 by textile engineer Joan Bertran as a *spin-off* between the SJD Barcelona Children’s Hospital ([HSJD](#)) and the Polytechnic University of BarcelonaTech ([UPC](#)), to develop a membrane as a local drug delivery system that allows surgeons, after the removal of a tumor, to cover the surgical bed with high concentrations of chemotherapy so that it can act directly on the affected area.

Thanks to the collaboration between HSJD researchers, who undertook the scientific and clinical aspects of the project, and the team of engineers from the UPC’s Institute of Textile Research and Industrial Cooperation of Terrassa ([INTEXTER](#)) which provided the technology for producing nanofibers, Cebiotex successfully created its first therapeutic solution, CEB-01, designed for the treatment of surgical beds for soft-tissue sarcoma (STS) using its Cebiotex® platform.

Backed by the technological support of Grifols Engineering, the biotech firm has a pre-industrial pilot plant with Good Manufacturing Practices (GMP) certification at PrasFarma.

In implementing its business project, Cebiotex has received financial support from equity crowdfunding campaigns with Capital Cell; from the Ship 2B Foundation; Inveready; family offices; the Center for the Development of Industrial Technology (Centro de Desarrollo Tecnológico Industrial, CDTI); the Ministry of Industry (ENISA), and the Ministry of Science (Challenges, Spanish National Plan for Scientific and Technical Research and Innovation 2017-2020) and the European Commission (SME Instrument Phase I).

It also has [‘Innovative SME’](#) accreditation and won the [Cecot Award for Innovation 2018](#).

More information:

Azucena Berea • Press Officer • Barcelona Science Park • Tel. (+34) 93 403 46 62 • aberea@pcb.upb.cat